Many biotech and pharmaceutical companies underestimate the impact of regulatory gaps until they receive critical questions from authorities, encounter submission delays, or face unexpected requests for additional data.
By that point, the consequences can include:
- Delayed clinical trials
- Delayed market access
- Increased development costs
- Lost investor confidence
The reality is that many of these risks can be identified and mitigated much earlier through strategic regulatory planning and critical dossier review.
At Starodub, we help biotech and pharma companies navigate complex development pathways by providing expertise in:
- Regulatory strategy
- Scientific Advice preparation
- CTA/IND and MAA/BLA submissions
- CMC and Quality documentation
- Non-clinical and clinical development
- FDA, EMA and global regulatory requirements
By integrating expertise across multiple disciplines, we provide a critical and holistic assessment of development programs, helping clients identify potential risks and regulatory gaps before they become obstacles.
Our goal is simple: Identify potential regulatory gaps before health authorities do.
Whether you’re preparing for a key submission, planning a Scientific Advice meeting, or evaluating your overall development strategy, an early regulatory assessment can save valuable time, resources, and unnecessary surprises later on.
Don’t wait for regulators to identify the gaps. Find them first.
Do you have a major regulatory milestone planned within the next 12 months? Send a message to info@starodub.nl to schedule a meeting to discuss your strategy and identify potential regulatory gaps before they impact your timelines.
